



## **ABcann Global Extends Research Agreement with the University of Guelph**

**June 26, 2017 – Ottawa, ON – ABcann Global Corporation (TSX-V:ABCN)** ("ABcann" or the "Company") is pleased to announce that it has amended and extended the research contract currently in place between its Canadian operating subsidiary, ABcann Medicinals Inc., and the University of Guelph, of Guelph, Ontario.

The agreement, which dates back to January 1, 2015, has been extended to December 31, 2018, with the option to extend if mutually agreed upon. The research is focused on Controlled Environment Production of Medicinal Cannabis and is being conducted at the Controlled Environment Systems Research Facility (CESRF) under the direction of Dr. Michael Dixon at the University of Guelph. A portion of the research is also being conducted within ABcann's research lab in Napanee which has been dedicated solely to the University of Guelph studies.

The multi-year research program is focused on a number of projects designed to enhance the ABcann process in terms of control, yield, quality and flexibility. Included are projects related to organic nutrient delivery and uptake, propagation protocols, optimizing controlled growth under different lighting configurations, and irrigation management strategies.

The \$1.4 million project "has already yielded results which have been incorporated into our growing systems," says Ken Clement, founder and Executive Chairman of ABcann, "and we fully expect to see further results which will give us a significant advantage over our competition. We have benefitted greatly from having the researchers and graduate students working with our team and we value our close working relationship with Dr. Dixon and his group."

"ABcann has pursued a unique approach to controlled environment production of cannabis designed to standardize the production and quality of medical compounds," says Dr. Mike Dixon, Director of the CESRF at Guelph. "Our research program in collaboration with ABcann represents a systematic and comprehensive approach to the development of the most sophisticated production technology in this industry sector."

ABcann is also pleased to announce the exercise of 9,241,766 warrants for gross proceeds of \$5,729,894. The warrants were originally issued in connection with private placements undertaken by ABcann Medicinals Inc. in 2014 and 2015

### **About the Controlled Environment Systems Research Facility (CESRF):**

ABcann has had a collaborative relationship with the CESRF since ABcann's early development stages. The CESRF research group is led by Dr. Michael Dixon, project leader for the Canadian research team investigating the contributions of plants to life support in space. Dr. Dixon formed the Space and Advanced Life Support Agriculture ("SALSA") program at the University of Guelph. The SALSA program currently represents Canada's prime contribution to the International Space program objectives in life support.

The CESRF provides a complete research venue suitable for measurement of plant growth, gas exchange, volatile organic compound ("VOC") evolution, and nutrient remediation in a precisely controlled environment. The CESRF is comprised of 24 sealed environment chambers, including 14 variable pressure plant growth hypobaric chambers capable of sustaining a vacuum. The CESRF personnel have extensive experience in the fields of plant physiology, environment analysis and sensor technology. ABcann's Vanluven Facility also has a room dedicated to the University of Guelph for CESRF's experiments using cannabis. The CESRF team assisted ABcann in developing the controlled growth environment systems currently being used at the Vanluven Facility.

### **About ABcann Global Corporation (TSX.V: ABCN):**

ABcann was one of the first companies to obtain a production license under the Marijuana for Medical Purposes Regulations, which it received on March 21, 2014. It obtained a sales license on December 31, 2015. ABcann's flagship facility, in Napanee, Ontario, contains proprietary plant-growing technology, including environmentally-controlled chambers capable of monitoring and regulating all variables in the growing process. This approach and the systems in place allow ABcann to produce organically grown and pesticide-free, high-yielding plants, which, in turn, can generate high-quality products that are consistent from batch to batch. ABcann is able to control environmental and nutrient demands, tailor-made for a particular strain of cannabis, without the variation that is typical when producing large quantities in less-controlled, larger rooms and greenhouse-type structures. ABcann's modular approach to systems technology eliminates scale-up risk and allows ABcann to locate anywhere in the world and maintain consistency and quality of product.

ABcann is expanding capacity in its current facility to approximately 30,000 sq ft and concurrently undertaking expansion into a new 150,000 sq ft facility in Napanee. ABcann is pursuing opportunities in Germany, Australia and other jurisdictions as well as exploring the development of multiple delivery vehicles.

### **ON BEHALF OF THE BOARD OF DIRECTORS**

*"Aaron Keay"*

Aaron Keay  
CEO and Director

For further information, please contact Aaron Keay by phone at (604) 323-6911 or by email at [aaron@abcannglobal.com](mailto:aaron@abcannglobal.com), or Leo Karabelas by phone at (416) 543-3120 or by email at [leo.k@abcannglobal.com](mailto:leo.k@abcannglobal.com)

**Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.**

**Disclaimer for Forward-Looking Information**

*Certain statements in this release are forward-looking statements, which are statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to: the duration of CESRF agreement, the expected benefits that the Company and its business will realize as a result of the extension of the CESRF agreement; and the scope of the Company's proposed expansions at its Vanluven and Kimmett facilities. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including: (i) changes to applicable legislation or regulatory requirements; (ii) changes to the anticipated costs of the expansions that require the Company to obtain additional capital or modify its development plans; (iii) a change in the relationship between the Company and CESRF; and (iv) other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors, and the more extensive risk factors included in the Company's filing statement dated March 31, 2017 which is available on SEDAR, carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. The forward-looking statements in this news release are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any such forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.*